<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8003.26990 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 1/10/2022 12:04:57 PM -->
      <!-- iXBRL Library version: 1.0.8003.27000 -->
      <!-- iXBRL Service Job ID: fb2b71e1-aa2c-4f0e-9427-c43ddb98c9b3 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:pasg="http://www.passagebio.com/20220110" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityCentralIndexKey" id="Tc_AGVtP5Ql4Ui46UsN9Cd32A_2_1">0001787297</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:AmendmentFlag" id="Tc_atYuGybrlUW-dX2K98Qubw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="pasg-20220110.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-10</xbrli:startDate><xbrli:endDate>2022-01-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_7ee2b51e_d2e2_4b1a_822d_6686134c7c3e"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">FORM </b><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:DocumentType" id="Narr_eMVc2_4-D06OgGvGxNqziw"><b style="font-weight:bold;text-transform:uppercase;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_dxrtelj8xUa6mXQszrHWOw"><b style="font-weight:bold;">January 10, 2022</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:20pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityRegistrantName" id="Narr_2PwbUMH77E2k0z4x69q6ow"><b style="font-weight:bold;">PASSAGE BIO, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_6c4b8138_aa3f_44ca_a36b_bc4c22a1c8db"></a><a id="Tc_05Ty9jEEdk-bF1EaRWLZUw_2_0"></a><a id="Tc_ubmgL50S80S0TXk8TmzfJw_2_1"></a><a id="Tc_xo04OKpVIU6sX8fQAOx-6A_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_po9cisDrfkm3pEJwMI1ZZA_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityFileNumber" id="Tc_VUsvsbRBzku7_vj1-jBWaQ_1_1"><b style="font-weight:bold;">001-39231</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityTaxIdentificationNumber" id="Tc_NU2naDreKE2FUykwIubKPg_1_2"><b style="font-weight:bold;">82-2729751</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_c405af10_290f_4a13_b389_4ea0a4fd35f3"></a><a id="Tc_MIjOHl6IdkKlJ6CS5Xt-aA_1_0"></a><a id="Tc_nQk1Ex3qkEKrBzOO6x9kYQ_2_0"></a><a id="Tc_wSoA7Gfpe0GOU55j0j2TJQ_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityAddressAddressLine1" id="Narr_Tl23kTJuW0GS4MgS0zdEdA"><b style="font-weight:bold;">One Commerce Square</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityAddressAddressLine2" id="Narr_HS3pio6ZOUSRMHlBEEWfzA"><b style="font-weight:bold;">2005 Market Street, 39</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">th</sup><b style="font-weight:bold;"> Floor</b></ix:nonNumeric> <br /><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityAddressCityOrTown" id="Narr_r83jeXrK20Wwo1KlDA1CkQ"><b style="font-weight:bold;">Philadelphia</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityAddressStateOrProvince" id="Narr_Fa-FNM77xU-v8IzP5e_nNg"><b style="font-weight:bold;">PA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:EntityAddressPostalZipCode" id="Tc_i3335KT5yEu_czuyQGfcfw_1_1"><b style="font-weight:bold;">19103</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:CityAreaCode" id="Narr_Y2fBKRXOckO950VkMgEKiA"><b style="font-weight:bold;">267</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:LocalPhoneNumber" id="Narr_0gGz3uIVmkqHS84zskcUzg"><b style="font-weight:bold;">866-0311</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_1axpRIeqik2pphrvE-xoNA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_gYHkLECSg0Cc1STfAUCYpQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_QqlpenxfxEulbggVizei-g"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_liTpTaSKxEGtHx-2eRrklQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p><a id="_bdbd50b8_94c6_42e7_9ee7_2e24043f0331"></a><a id="Tc_Y92JibLzmEOj5KG9BHJG0Q_1_0"></a><a id="Tc_XiUlhrELz0WZz6nQISxr0A_1_1"></a><a id="Tc_7xeHm0dcFU2IPWU58YBpRw_1_2"></a><a id="Tc_-xUegOW3okCN8NK79ftTFw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.05092621%;padding-left:0.5pt;padding-right:0.5pt;width:100.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:19.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:2pt 0pt 2pt 0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:Security12bTitle" id="Tc_PzDzjDopKUSjmc5gbYrk2Q_2_0">Common Stock, $0.0001 Par Value Per Share</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:2pt 0pt 2pt 0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" name="dei:TradingSymbol" id="Tc_IZ_9zW3fvEiapRQSnuXk1w_2_1">PASG</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:2pt 0pt 2pt 0pt;"><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_ezbdlFBoR0iqXF_-eIw_1g">The Nasdaq Stock Market LLC</ix:nonNumeric><br />(Nasdaq Global Select Market)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="color:#211d1e;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="color:#211d1e;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_soqMWT6egUSJFgyeDLpCzQ"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#211d1e;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric contextRef="Duration_1_10_2022_To_1_10_2022_i99x-ccdY0yecprBFmx6Og" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_Pw5JMsPwyk-jKEUFHqnu7A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_8c5b0842_7f13_48ca_8267_849d37afaca0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 2.</b><b style="font-weight:bold;">02 Results of Operations and Financial Condition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="background:#ffffff;">On January 10, 2022, Passage Bio, Inc. (the </span><span style="font-style:italic;font-weight:bold;background:#ffffff;">&#8220;Company&#8221;</span><span style="background:#ffffff;">) will</span> present a corporate presentation (the &#8220;<span style="font-style:italic;font-weight:bold;">JPM Presentation</span>&#8221;) at the J.P. Morgan 40th Annual Healthcare Conference (&#8220;<span style="font-style:italic;font-weight:bold;">JPM</span>&#8221;), which reports the preliminary, unaudited amount of the Company&#8217;s cash, cash equivalents and marketable securities position as of December 31, 2021, as approximately $316 million, which the Company expects <span style="background:#ffffff;">will enable it to fund its operating expenses and capital expenditure requirements&#160;to year-end 2023</span>. This amount is preliminary, unaudited and may change, were prepared by management and are based on the most current information available to management, and are subject to completion by management of the financial statements as of and for the year ended December 31, 2021, including completion of the review procedures, final adjustments and other developments that may arise between now and the time the financial results for this period are finalized, and completion of the audit of such financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 7.01 Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="background:#ffffff;">In addition to the Company&#8217;s presentation of the JPM Presentation</span>, the Company also issued a press release regarding updates to the Company&#8217;s clinical programs, research-stage pipeline programs, and manufacturing plans on January 10, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:22.05pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:22.05pt;background:#ffffff;margin:0pt;">A copy of the press release and JPM Presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on&#160;Form&#160;8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt;">The information in this Item 7.01, including Exhibits 99.1 and 99.2 to this report, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Item 7.01 and in the accompanying Exhibits 99.1 and 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 8.01&#160;Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="background:#ffffff;">The information set forth in Item 2.02 above is incorporated by reference into this Item 8.01.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><i style="font-style:italic;">Clinical and Research-Stage Pipeline Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company announced the following updates with respect to its clinical and research-stage pipeline programs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In its Imagine-1 clinical trial, it expects to dose the first patients in cohorts 2 and 3 in early 2022.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The target of its previously undisclosed program in adult central nervous system disorders is PRKN for Parkinson&#8217;s disease. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For its metachromatic leukodystrophy (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">MLD</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) program (PBML04), the Company&#8217;s current approach is to use intra cisterna magna (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">ICM</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) route of administration and an AAVhu68 capsid to deliver a functional </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ARSA</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> gene.  Preclinical data showed that PBML04 delivered by intracerebroventricular (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">ICV</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8221;) administration dose-dependently reduced functional decline and increased survival in a novel MLD mouse model. The company plans to submit an Investigational New Drug application for the Phase 1/2 clinical program for MLD in mid-year 2022.  </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For its </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Charcot-Marie-Tooth Type 2A (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">CMT2A</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> program (PBCM06), the Company&#8217;s current approach is to use ICM route of administration and AAV delivery of a miRNA and gene combination to knockdown mutant and replace with functional MFN2.  Preclinical pilot data identified lead construct that ameliorates distal limb weakness (grip strength) after ICV delivery in mice with a mutation in the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">MFN2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> gene.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For its amyotrophic lateral sclerosis (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">ALS</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8221;) program (PBAL05), the Company&#8217;s current approach is to use ICM route of administration and AAV delivery of a miRNA and gene combination to knockdown mutant and replace with functional C9orf72.  Preclinical pilot data showed that AAV-C9miRNA normalized elevated toxic poly(GP) dipeptide repeat protein levels in mouse brains with a mutation in the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">C9-ALS</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> gene.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Manufacturing </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company expects to operationalize a new pilot manufacturing suite by year-end 2022 at the Princeton West Innovation Campus in Hopewell, N.J., for scale-up capability to support its research and development pipeline as well as future development plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:48.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;9.01</b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)&#160;Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:87.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:10.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:89.46%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20220110xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Passage Bio, Inc. press release dated January 10, 2022.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.2</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20220110xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Corporate Presentation.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_d430a497_781d_4f78_88b9_008ea972b624"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PASSAGE BIO, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 10, 2022</p></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "pasg-20220110x8k.htm", "description": "8-K", "secsgml_size_bytes": 49678}]
{"company-data": {"conformed-name": "Passage BIO, Inc.", "cik": "0001787297", "assigned-sic": "2836", "irs-number": "822729751", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39231", "film-number": "22519742"}, "business-address": {"street1": "ONE COMMERCE SQUARE", "street2": "2005 MARKET STREET, 39TH FLOOR", "city": "PHILADELPHIA", "state": "PA", "zip": "19103", "phone": "2678660312"}, "mail-address": {"street1": "ONE COMMERCE SQUARE", "street2": "2005 MARKET STREET, 39TH FLOOR", "city": "PHILADELPHIA", "state": "PA", "zip": "19103"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 10, 2022
PASSAGE BIO, INC.
(Exact name of registrant as specified in its charter)
​
​
​
​
Delaware
001-39231
82-2729751
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
​
​
​
One Commerce Square
2005 Market Street, 39
th
Floor
Philadelphia
,
PA
19103
(Address of principal executive offices)
(Zip Code)
​
(
267
)
866-0311
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
​
​
​
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per Share
PASG
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
Item 2.
02 Results of Operations and Financial Condition
​
On January 10, 2022, Passage Bio, Inc. (the
"Company"
) will
present a corporate presentation (the "
JPM Presentation
") at the J.P. Morgan 40th Annual Healthcare Conference ("
JPM
"), which reports the preliminary, unaudited amount of the Company's cash, cash equivalents and marketable securities position as of December 31, 2021, as approximately $316 million, which the Company expects
will enable it to fund its operating expenses and capital expenditure requirements to year-end 2023
. This amount is preliminary, unaudited and may change, were prepared by management and are based on the most current information available to management, and are subject to completion by management of the financial statements as of and for the year ended December 31, 2021, including completion of the review procedures, final adjustments and other developments that may arise between now and the time the financial results for this period are finalized, and completion of the audit of such financial statements.
​
Item 7.01 Regulation FD Disclosure.
​
In addition to the Company's presentation of the JPM Presentation
, the Company also issued a press release regarding updates to the Company's clinical programs, research-stage pipeline programs, and manufacturing plans on January 10, 2022.
A copy of the press release and JPM Presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
​
The information in this Item 7.01, including Exhibits 99.1 and 99.2 to this report, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Item 7.01 and in the accompanying Exhibits 99.1 and 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
​
Item 8.01 Other Events.
​
The information set forth in Item 2.02 above is incorporated by reference into this Item 8.01.
​
Clinical and Research-Stage Pipeline Programs
​
The Company announced the following updates with respect to its clinical and research-stage pipeline programs:
●
In its Imagine-1 clinical trial, it expects to dose the first patients in cohorts 2 and 3 in early 2022.
​
●
The target of its previously undisclosed program in adult central nervous system disorders is PRKN for Parkinson's disease.
​
●
For its metachromatic leukodystrophy ("
MLD
") program (PBML04), the Company's current approach is to use intra cisterna magna ("
ICM
") route of administration and an AAVhu68 capsid to deliver a functional
ARSA
gene.  Preclinical data showed that PBML04 delivered by intracerebroventricular ("
ICV
") administration dose-dependently reduced functional decline and increased survival in a novel MLD mouse model. The company plans to submit an Investigational New Drug application for the Phase 1/2 clinical program for MLD in mid-year 2022.
​
●
For its
Charcot-Marie-Tooth Type 2A ("
CMT2A
")
program (PBCM06), the Company's current approach is to use ICM route of administration and AAV delivery of a miRNA and gene combination to knockdown mutant and replace with functional MFN2.  Preclinical pilot data identified lead construct that ameliorates distal limb weakness (grip strength) after ICV delivery in mice with a mutation in the
MFN2
gene.
​
●
For its amyotrophic lateral sclerosis ("
ALS
") program (PBAL05), the Company's current approach is to use ICM route of administration and AAV delivery of a miRNA and gene combination to knockdown mutant and replace with functional C9orf72.  Preclinical pilot data showed that AAV-C9miRNA normalized elevated toxic poly(GP) dipeptide repeat protein levels in mouse brains with a mutation in the
C9-ALS
gene.
2
Manufacturing
​
The Company expects to operationalize a new pilot manufacturing suite by year-end 2022 at the Princeton West Innovation Campus in Hopewell, N.J., for scale-up capability to support its research and development pipeline as well as future development plans.
​
​
Item 9.01
Financial Statements and Exhibits.
​
(d) Exhibits
​
Exhibit No.
Description
99.1
​
Passage Bio, Inc. press release dated January 10, 2022.
99.2
​
Corporate Presentation.
104
​
Cover Page Interactive Data File (formatted as Inline XBRL).
​
​
​
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
PASSAGE BIO, INC.
​
​
​
Date: January 10, 2022
By:
/s/ Simona King
​
​
Simona King
​
​
Chief Financial Officer
​
​
​
4